RA Capital Management
Latest statistics and disclosures from Ra Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ASND, RYTM, PCVX, RNA, CDTX, and represent 46.18% of Ra Capital Management's stock portfolio.
- Added to shares of these 10 stocks: NUVL (+$108M), Vor Biopharma (+$97M), BLTE (+$65M), RNA (+$60M), MLYS (+$45M), PEPG (+$43M), Lb Pharmaceuticals (+$28M), ASMB (+$26M), CTNM (+$25M), IVVD (+$19M).
- Started 16 new stock positions in SABS, CTNM, QURE, IVVD, GKOS, EXAS, Vor Biopharma, BLTE, PRME, ASMB. Lb Pharmaceuticals, NUVL, EVH, PGNY, DSGN, INSP.
- Reduced shares in these 10 stocks: DYN (-$93M), VOR (-$64M), RXST (-$48M), TRML (-$41M), ELVN (-$17M), HNGE (-$16M), OMDA (-$7.3M), BBNX (-$7.3M), TXG (-$5.5M), MBX.
- Sold out of its positions in ACHC, BBNX, DYN, ELVN, HNGE, MBX, OMDA, TARA, RXST, TXG. TRML, VOR.
- Ra Capital Management was a net buyer of stock by $289M.
- Ra Capital Management has $8.1B in assets under management (AUM), dropping by 36.72%.
- Central Index Key (CIK): 0001346824
Tip: Access up to 7 years of quarterly data
Positions held by RA Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Ra Capital Management
Ra Capital Management holds 67 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Ascendis Pharma A/s - SH (ASND) | 25.2 | $2.0B | 10M | 198.81 |
|
|
| Rhythm Pharmaceuticals SH (RYTM) | 7.1 | $574M | +2% | 5.7M | 100.99 |
|
| Vaxcyte SH (PCVX) | 5.3 | $431M | 12M | 36.02 |
|
|
| Avidity Biosciences SH (RNA) | 4.6 | $377M | +18% | 8.6M | 43.57 |
|
| Cidara Therapeutics SH (CDTX) | 4.0 | $322M | 3.4M | 95.76 |
|
|
| Sionna Therapeutics SH (SION) | 3.8 | $307M | 10M | 29.41 |
|
|
| 89bio SH (ETNB) | 3.6 | $292M | 20M | 14.70 |
|
|
| Newamsterdam Pharma Co Nv SH (NAMS) | 3.6 | $288M | 10M | 28.44 |
|
|
| Mineralys Therapeutics SH (MLYS) | 3.4 | $278M | +19% | 7.3M | 37.92 |
|
| Janux Therapeutics SH (JANX) | 3.4 | $274M | 11M | 24.44 |
|
|
| Arcellx SH (ACLX) | 3.1 | $249M | 3.0M | 82.10 |
|
|
| Lenz Therapeutics SH (LENZ) | 2.4 | $195M | 4.2M | 46.58 |
|
|
| Tyra Biosciences SH (TYRA) | 2.1 | $171M | 12M | 13.99 |
|
|
| Edgewise Therapeutics SH (EWTX) | 2.1 | $169M | +5% | 10M | 16.22 |
|
| Wave Life Sciences SH (WVE) | 1.6 | $133M | 18M | 7.32 |
|
|
| Septerna SH (SEPN) | 1.6 | $132M | 7.0M | 18.81 |
|
|
| Dianthus Therapeutics SH (DNTH) | 1.4 | $113M | 2.9M | 39.35 |
|
|
| Bicara Therapeutics SH (BCAX) | 1.4 | $110M | 7.0M | 15.79 |
|
|
| Gh Research SH (GHRS) | 1.4 | $110M | 7.7M | 14.30 |
|
|
| Ars Pharmaceuticals SH (SPRY) | 1.3 | $109M | 11M | 10.05 |
|
|
| Nuvalent Inc-a SH (NUVL) | 1.3 | $108M | NEW | 1.2M | 86.48 |
|
| Disc Medicine SH (IRON) | 1.3 | $104M | 1.6M | 66.08 |
|
|
| Vor Biopharma SH | 1.2 | $97M | NEW | 2.0M | 48.72 |
|
| Fulcrum Therapeutics SH (FULC) | 1.2 | $94M | 10M | 9.20 |
|
|
| Pepgen SH (PEPG) | 1.1 | $93M | +87% | 20M | 4.62 |
|
| Geron Corp SH (GERN) | 1.0 | $83M | 60M | 1.37 |
|
|
| Taysha Gene Therapies SH (TSHA) | 0.9 | $77M | 24M | 3.27 |
|
|
| Belite Bio Inc - SH (BLTE) | 0.8 | $65M | NEW | 875k | 74.00 |
|
| Climb Bio SH (CLYM) | 0.8 | $63M | 31M | 2.01 |
|
|
| Scholar Rock Holding Corp SH (SRRK) | 0.5 | $44M | +2% | 1.2M | 37.24 |
|
| Structure Therapeutics SH (GPCR) | 0.5 | $43M | 1.5M | 28.00 |
|
|
| Monopar Therapeutics SH (MNPR) | 0.5 | $42M | 511k | 81.67 |
|
|
| 4d Molecular Therapeutics In SH (FDMT) | 0.5 | $40M | 4.6M | 8.69 |
|
|
| Solid Biosciences SH (SLDB) | 0.4 | $36M | 5.8M | 6.17 |
|
|
| Metsera SH (MTSR) | 0.4 | $35M | 676k | 52.33 |
|
|
| Artiva Biotherapeutics SH (ARTV) | 0.3 | $28M | 9.9M | 2.87 |
|
|
| Lb Pharmaceuticals SH | 0.3 | $28M | NEW | 1.8M | 15.79 |
|
| Travere Therapeutics SH (TVTX) | 0.3 | $28M | 1.2M | 23.90 |
|
|
| Assembly Biosciences SH (ASMB) | 0.3 | $26M | NEW | 1.0M | 25.60 |
|
| Acumen Pharmaceuticals SH (ABOS) | 0.3 | $26M | 15M | 1.71 |
|
|
| Contineum Therapeutics Inc-a SH (CTNM) | 0.3 | $25M | NEW | 2.1M | 11.75 |
|
| Nkarta SH (NKTX) | 0.3 | $22M | 11M | 2.07 |
|
|
| Larimar Therapeutics SH (LRMR) | 0.2 | $20M | 6.0M | 3.23 |
|
|
| Invivyd SH (IVVD) | 0.2 | $19M | NEW | 17M | 1.10 |
|
| Tango Therapeutics SH (TNGX) | 0.2 | $17M | 2.0M | 8.40 |
|
|
| Prime Medicine SH (PRME) | 0.2 | $17M | NEW | 3.0M | 5.54 |
|
| Arcus Biosciences SH (RCUS) | 0.2 | $16M | 1.1M | 13.60 |
|
|
| Acrivon Therapeutics SH (ACRV) | 0.2 | $15M | 8.3M | 1.81 |
|
|
| Werewolf Therapeutics SH (HOWL) | 0.2 | $13M | 6.7M | 1.97 |
|
|
| Uniqure Nv SH (QURE) | 0.1 | $12M | NEW | 200k | 58.37 |
|
| Eledon Pharmaceuticals SH (ELDN) | 0.1 | $9.2M | 3.6M | 2.59 |
|
|
| Jade Biosciences SH (JBIO) | 0.1 | $9.2M | 1.1M | 8.63 |
|
|
| Sab Biotherapeutics SH (SABS) | 0.1 | $8.8M | NEW | 4.4M | 2.01 |
|
| Inspire Medical Systems SH (INSP) | 0.1 | $8.5M | NEW | 115k | 74.20 |
|
| Cytomx Therapeutics SH (CTMX) | 0.1 | $8.5M | 2.7M | 3.19 |
|
|
| Avalo Therapeutics SH (AVTX) | 0.1 | $8.4M | -28% | 663k | 12.71 |
|
| Perceptive Capital Solutions SH (PCSC) | 0.1 | $8.0M | 750k | 10.60 |
|
|
| Surrozen SH (SRZN) | 0.1 | $7.8M | 603k | 12.88 |
|
|
| Genedx Holdings Corp SH (WGS) | 0.1 | $6.3M | 58k | 107.74 |
|
|
| Adicet Bio SH (ACET) | 0.1 | $6.1M | 7.5M | 0.81 |
|
|
| Newamsterdam Pharma Co Nv-27 SH (NAMSW) | 0.1 | $5.7M | 333k | 17.11 |
|
|
| Evolent Health Inc - A SH (EVH) | 0.1 | $4.9M | NEW | 579k | 8.46 |
|
| Glaukos Corp SH (GKOS) | 0.1 | $4.4M | NEW | 54k | 81.55 |
|
| Design Therapeutics SH (DSGN) | 0.0 | $3.6M | NEW | 476k | 7.53 |
|
| Exact Sciences Corp SH (EXAS) | 0.0 | $3.0M | NEW | 55k | 54.71 |
|
| Inflarx Nv SH (IFRX) | 0.0 | $2.6M | 2.0M | 1.34 |
|
|
| Progyny SH (PGNY) | 0.0 | $2.1M | NEW | 97k | 21.52 |
|
Past Filings by Ra Capital Management
SEC 13F filings are viewable for Ra Capital Management going back to 2010
- Ra Capital Management 2025 Q3 filed Nov. 14, 2025
- Ra Capital Management 2025 Q2 filed Aug. 14, 2025
- Ra Capital Management 2025 Q1 filed May 15, 2025
- Ra Capital Management 2024 Q4 filed Feb. 14, 2025
- Ra Capital Management 2024 Q3 filed Nov. 14, 2024
- Ra Capital Management 2024 Q2 filed Aug. 14, 2024
- Ra Capital Management 2024 Q1 amended filed May 17, 2024
- Ra Capital Management 2024 Q1 filed May 15, 2024
- Ra Capital Management 2023 Q4 filed Feb. 14, 2024
- Ra Capital Management 2023 Q3 amended filed Nov. 15, 2023
- Ra Capital Management 2023 Q3 filed Nov. 14, 2023
- Ra Capital Management 2023 Q2 filed Aug. 14, 2023
- Ra Capital Management 2023 Q1 filed May 15, 2023
- Ra Capital Management 2022 Q4 filed Feb. 14, 2023
- Ra Capital Management 2022 Q3 filed Nov. 14, 2022
- Ra Capital Management 2022 Q2 filed Aug. 15, 2022